Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna received the latest telling-off after the U.K. drug marketing watchdog reviewed social media posts and other materials related to the NextCOVE clinical trial of its COVID-19 vaccine.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Moderna (MRNA) cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects $1.5 billion to $2 ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...